Eating disorders are on the rise. GLP-1s could make things worse.
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
What happened
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
Why it matters
The development may change operating conditions or market expectations around AI. Further confirmation and measurable outcomes matter.
Affected entities
View evidence
1 reports · 1 original report · 1 independent
- MIT Technology ReviewPrimary source · Supports · EN · 100%Eating disorders are on the rise. GLP-1s could make things worse. ↗
Claims
- Eating disorders are on the rise. GLP-1s could make things worse. Reported
Conflicts
No material conflict detected in the available evidence.
Timeline
- First reported
Market move following event
Market reaction is not yet available for this asset and time window.